Skip to main content
Caplight Logo









ExosomePlus

ExosomePlus

Private
South KoreaHealthcare & Life Scienceshttp://exosomeplus.com/

Last Round

Early Funding

Apr 9, 2019

Total Funding Raised

$2.37M

Company Overview

ExosomePlus is a biotechnology company that develops extracellular vesicle isolation and characterization platforms for regenerative therapy and diagnostic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

exosome isolationextracellular vesiclesEVexosome characterizationregenerative medicinebiotech research toolslab consumablesquality control servicesQCmesenchymal stem cellMSCdrug developmentexosome diagnosticsliquid biopsybiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ExosomePlus Comparables

Compare ExosomePlus with similar companies based on industry and business-model similarity.

ExosomePlus comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xenohelix Co., Ltd.
79%
Cell Guidance Systems
78%
CellBio Scientific
77%

ExosomePlus Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 9, 2019

ExosomePlus Investors

Notable investors and investment history

ExosomePlus investors
InvestorRounds
CKD Venture CapitalEarly Funding
DAYLI PartnersEarly Funding
POSCO Technology InvestmentEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors increased by 113% MoM.

  • Jan 21, 2025

    Monthly visitors grew 732% MoM, from 50 to 416.

ExosomePlus Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ExosomePlus Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ExosomePlus's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea
Employee Range2
Year Founded2018
Last FundingApr 9, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?